A Phase III Clinical Trial on the Safety and Efficacy of CBT-001 in Patients With Pterygium
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the safety and efficacy of 0.1% and 0.2% CBT-001 emulsion dosed
twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and
preventing pterygium progression in eyes with pterygia.